We are live on ! Find out more
RARE icon

Ultragenyx Pharmaceutical
RARE

81 hedge funds and large institutions have $816M invested in Ultragenyx Pharmaceutical in 2014 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 31 increasing their positions, 26 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

56% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 9

19% more repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 26

17% more call options, than puts

Call options by funds: $293K | Put options by funds: $251K

5% more funds holding

Funds holding: 77 → 81 (+4)

0% more capital invested

Capital invested by funds: $815M → $816M (+$1.1M)

Holders
81
Holders Change
+4
Holders Change %
+5.19%
% of All Funds
2.33%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
14
Increased
31
Reduced
26
Closed
9
Calls
$293K
Puts
$251K
Net Calls
+$42K
Net Calls Change
+$42K

Top Buyers

1
Fidelity Investments
Fidelity Investments
Massachusetts
+$37.4M
2
Lord, Abbett & Co
Lord, Abbett & Co
New Jersey
+$7.32M
3
Citadel Advisors
Citadel Advisors
Florida
+$6.34M
4
CI
Cowen Inc
New York
+$5.78M
5
Goldman Sachs
Goldman Sachs
New York
+$2.67M

Top Sellers

1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$5.67M
2
TCP
Tourbillon Capital Partners
New York
-$3.91M
3
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$3.45M
4
Jennison Associates
Jennison Associates
New York
-$2.68M
5
Millennium Management
Millennium Management
New York
-$2.63M
Name Holding Trade Value Shares
Change 		Change in
Stake
Citigroup
76
Citigroup
New York
$14K +$12.4K +301 +1,254%
Teacher Retirement System of Texas
77
Teacher Retirement System of Texas
Texas
$12K +$10.7K +261 New
Bank of Montreal
78
Bank of Montreal
Ontario, Canada
$8K +$7K +170 New
BlackRock
79
BlackRock
New York
$7K -$441K -10,700 -98%
Barclays
80
Barclays
United Kingdom
$6K -$2.55K -62 -34%
MAA
81
Managed Account Advisors
New Jersey
$5K -$2.96K -72 -41%
TCP
82
Tourbillon Capital Partners
New York
– -$3.91M -80,000 Closed
Principal Financial Group
83
Principal Financial Group
Iowa
– -$1.29M -26,400 Closed
QF
84
QVT Financial
New York
– -$1.22M -25,000 Closed
BG
85
BlackRock Group
United Kingdom
– -$1.11M -22,623 Closed
LCG
86
Lisanti Capital Growth
New York
– -$714K -14,595 Closed
TD Asset Management
87
TD Asset Management
Ontario, Canada
– -$284K -5,800 Closed
ACH
88
ArrowMark Colorado Holdings
Colorado
– -$273K -5,586 Closed
COPPSERS
89
Commonwealth of Pennsylvania Public School Employees Retirement System
Pennsylvania
– -$216K -4,415 Closed
TRCT
90
Tower Research Capital (TRC)
New York
– -$15K -314 Closed
1 2 3
4

RARE Hedge Fund Activity: Q2 2014 in Review

81 of the 3,479 institutional investors tracked by Wall St. Rank reported a position in Ultragenyx Pharmaceutical (RARE) for Q2 2014, worth a combined $816M — up 0.14% from $815M a quarter earlier.

Buyers outnumbered sellers: 14 funds opened new RARE positions and 9 closed out — a net gain of 5 holders — while 31 added to existing stakes and 26 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $37.4M. The largest seller was T. Rowe Price Associates, cutting an estimated $5.67M.

  • 81 institutional investors held Ultragenyx Pharmaceutical (RARE) as of Q2 2014, up from 77 in Q1 2014.
  • Funds reported $816M of Ultragenyx Pharmaceutical stock for Q2 2014, up 0.14% quarter-over-quarter.
  • 14 funds opened new Ultragenyx Pharmaceutical positions in Q2 2014 and 9 closed out, a net change of +5 holders.
  • The largest Ultragenyx Pharmaceutical buyer in Q2 2014 was Fidelity Investments, an estimated $37.4M added.
  • The largest Ultragenyx Pharmaceutical seller in Q2 2014 was T. Rowe Price Associates, an estimated $5.67M sold.

Based on aggregated 13F filings for Q2 2014.